Abstract:Background In current years, the CRISPR (clustered regularly interspaced short palindromic repeats) based strategies have emerged as the most promising molecular tool in the field of gene editing, intracellular imaging, transcriptional regulation and biosensing. However, the recent CRISPR-based diagnostic technologies still require the incorporation of other amplification strategies (such as polymerase chain reaction) to improve the cis/trans cleavage activity of Cas12a, which complicates the detection workflow and lack of a uniform compatible system to respond to the target in one pot. Results To better fully-functioning CRISPR/Cas12a, we reported a novel technique for straightforward nucleic acid detection by incorporating enzyme-responsive steric hindrance-based branched inhibitors with CRISPR/AsCas12a methodology. The construction-transferable branched inhibitors coupled with a specific overhang flap induce spatial steric effects and result in the loss of the binding ability of Cas12a, which inhibits the activity of Cas12a. Target as the input signal would trigger the site-directed APE1 enzyme incision of the inhibitors, thus transforming the conformation of the inhibitors into split activators to illumine the CRISPR/AsCas12a catalyst system. At the same time, we found that APE1 could drive the enzymatic positive feedback circuit and exhibited considerably high amplification efficiency to enhance the detection ability of nucleic acids. Besides, our method provides universal platforms and can be realized in real-time and one-pot detection of HIV-1 DNA by replacing the inhibitors and crRNA with different target recognition sequences. Significance and Novelty Overall, due to the high programmability of the nucleic acid network, this work proposed a feasible way to use the steric hindrance-based inhibitors as a switchable element, decorating the CRISPR/Cas12a-based strategy equipment for molecular diagnostics. Besides, this strategy could offer a simple tool for detecting trace nucleic acid, which opens avenues for future clinical application.

Programmed aptamer target chain reaction (ATCR) for smart therapeutic inhibitor development

Molecular assembly for high-performance bivalent nucleic acid inhibitor

Programmable Repurposing of Existing Drugs as Pharmaceutical Elements for the Construction of Aptamer–Drug Conjugates

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

In Silico Design and Validation of High-Affinity RNA Aptamers Targeting Epithelial Cellular Adhesion Molecule Dimers

Blocker-SELEX: A Structure-guided Strategy for Developing Inhibitory Aptamers Disrupting Undruggable Transcription Factor Interactions

Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future

Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy

Aptamer and Aptamer Pharmaceuticals

Aptamer-based protein molecule detection via cyclic reverse transcription coupling with self-priming hairpin-triggered CRISPR-Cas12a system

Reversible and site-specific immobilization of β2-adrenergic receptor by aptamer-directed method for receptor-drug interaction analysis

Chemical Amplification-Enabled Topological Modification of Nucleic Acid Aptamers for Enhanced Cancer-Targeted Theranostics

Engineered Aptamer‐Organic Amphiphile Self‐Assemblies for Biomedical Applications: Progress and Challenges

A dynamic DNA tetrahedron framework for active targeting

Molecular Engineering of Aptamer Self-Assemblies Increases in Vivo Stability and Targeted Recognition

Structure-switchable branched inhibitors regulate the activity of CRISPR-Cas12a for nucleic acid diagnostics

The First-in-human Whole-body Dynamic Pharmacokinetics Study of Aptamer

A Novel Rational PROTACs Design and Validation via AI-Driven Drug Design Approach

A homodimeric aptamer variant generated from ligand-guided selection activates T-cell receptor cluster of differentiation three complex

Aptamers as therapeutics in cardiovascular diseases.